Posted innews OB/GYN & Women's Health Oncology
Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical Trial
Five-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.